

## The New Jersey Journal of Pharmacy

### Author Guidelines

#### Manuscript Submission

All journal article submissions should be emailed to [njpharmacists@gmail.com](mailto:njpharmacists@gmail.com)

**The NJPhA Journal of Pharmacy thanks you for your submission for publication. We publish a quarterly journal comprising a Winter, Spring, Summer and Fall edition. Please note that the anticipated length of time from submission to publication may be up to six months.** The current estimated time from submission to publication is 6 months at a minimum, in part because the Journal does not have peer reviewers “on standby.” It takes time to ensure reviewers have the expertise/experience to approach the material appropriately and fairly. Editing, communication with the author(s), and layout take additional time and effort. On occasion, an article may be returned to the author for edits/corrections after the peer review process. The Editor and the Publisher reserve the right to withhold publication of any article absent the requested revisions. After completion of the review process, an acceptance or rejection email will be sent to the corresponding author.

An article submission does not assure a published article for the upcoming journal edition. Since the journal combines articles, continuing education activity and other association news, the number and length of articles that can potentially be printed will vary in each publication.

#### Manuscript Content/Format Guidelines

##### Cover Page

Authors should include a cover page and disclosure statement with all submissions. The cover page and disclosure statements can be found at the end of this document

##### Content Categories and Recommended Word Limits

Authors should observe the following recommended word-count limits when creating content. If the topic merits greater length, the author should consider breaking up the article into 2 clearly-marked parts, to be published in consecutive issues and communicate this intent to the journal editor(s) upon submission.

- **Original research report – Word limit: 2500.** Should be organized into distinct subsections, such as Background/Purpose, Materials and Methods, Results, and Discussion/Conclusion(s). Should also include a structured abstract that follows the organization described above (abstract word limit: 300 words). [Authors should ensure that the abstract contains all the key words/concepts that the article addresses for future indexing purposes.]
- **Abstract – Word limit 300**
- **Review article – Word limit: 2500.** Should be comprehensive and contain essential information on a particular subject relevant to the profession of pharmacy. .
- **Pharmacy practice spotlight – Word limit: 1500.** Highlights a particular pharmacy practice in New Jersey that demonstrates advances in care or provides specialized care. , if any, of the journal issue in which the article appears.

- **Drug comparison article – Word limit: 2000.** Objectively compares drugs within a class or in different classes with the same indication(s).
- **New drug approval – Word limit: 1000.** Comprises a brief review of drug products that have been recently approved (approximately within the past year) by the United States Food and Drug Administration.
- **Case report – Word limit: 1500.** Consists of unique patient case(s) that are of interest to pharmacists.
- **Disruptive innovation report – Word limit: 350.** Should include medications or products that are still in the “pipeline” (as yet unapproved) and are expected to have significant clinical implications, such as a novel drug target or mechanism of action, or heightened safety profile. Must include: name/nomenclature, pharmacology, expected use, expected patient population, phase/where it is in the pipeline/expected release date, what differentiates it from products already on the market.
- **Guest editorial – Word limit: 750.** Should focus on areas related to clinical pharmacy practice, research, or education. Authors interested in pursuing ideas that fall outside these categories should contact the editors, at [nhpharmacists@gmail.com](mailto:nhpharmacists@gmail.com)

### Acknowledgments

Individuals who have made significant contributions, but do not qualify as authors, should be acknowledged (if they agree to be named) at the end of the article. For additional information on authorship, consult the International Committee of Medical Journal Editors authorship criteria.

### Permissions

Written proof of permission from the person or entity that holds copyright is necessary to use or adapt previously published tables, figures, or other copyrighted illustrative material. Such re-use or adaption must be explicated and credited as such.

### Style Guidelines

- Manuscript should be prepared in Microsoft Word (no PDFs) using a 12-point font (Times New Roman or Arial font) and an 8.5 x 11.0 inch page size. All pages should be double-spaced and numbered. As submissions will be blinded for review, do not include identifying information anywhere except on the cover page.
- Graphs, tables, and diagrams will be printed in monochrome/grayscale and at a default size of ¼ page. Authors should make sure all details and captions are legible at that scale, in that format, and concise in nature.
- Abbreviations and acronyms should be defined upon first use in the body of the paper.
- The brand name of a product should be followed immediately by the generic name in parentheses. Alternately, the generic name can be followed immediately by at least 2 brand names cited as examples, in parentheses. The generic, not brand, name of a drug should be used consistently in the manuscript. If a brand or generic name for a product is not yet available, use the company code name.
- Discussion should occur in generic, nonspecific terms. For example, authors should avoid mention of the manufacturer by name, the kind of packaging, product-specific handling/administration requirements, or price that is promotional in nature.

- Use: AMA Manual of Style, 10th Ed  
<http://www.amamanualofstyle.com/view/10.1093/jama/9780195176339.001.0001/med-9780195176339>
- References:
  - All references must appear in the text as superscripted Arabic numerals, and be cited consecutively. This applies for references in text, tables, and figure legends; reference citations are not used in the abstract.
  - Citation format:
    - Journal names should be abbreviated as they appear in PubMed. Those not appearing in PubMed should be spelled out. Articles "In press" must include the title of the journal that has accepted the paper.
    - List all authors when there are 6 or fewer; with 7 or more authors, list the first 3, followed by et al.
    - Articles that have been published online ahead of print, include the date published online (Epub date) in place of the numerical portion of the citation.
- Citation examples:
  - Articles:
    - Baldwin DS, Heldbo Reines E, Guiton C, Weiller E. Escitalopram therapy for major depression and anxiety disorders. *Ann Pharmacother.* 2007;41:1583-1592.
    - Wormser GP, Ramanathan R, Nowakowski J, et al. Duration of antibiotic therapy for early Lyme disease. *Ann Intern Med.* 2003;138:697-705.
    - Cies JJ, Shankar V. Nephrotoxicity in Patients with Vancomycin Trough Concentrations of 15-20 µg/ml in a Pediatric Intensive Care Unit. *Pharmacotherapy.* 2013 Mar 7. [Epub ahead of print]
  - Electronic sources:
    - Centers for Disease Control and Prevention. Malaria. <http://www.dpd.cdc.gov/dpdx/HTML/Malaria.htm>. Accessed March 21, 2013.
  - Abstracts:
    - Rao N, Knebel W, Bergsma T, et al. Population pharmacokinetics of istradefylline (abstract 13). *J Clin Pharmacol.* 2007;47:1185.
  - Books:
    - Goldberg L, Elliot DL. *Exercise for Prevention and Treatment of Illness.* Philadelphia, Pa: FA Davis Co; 1994.
  - Book chapter:
    - Gamble VN. On becoming a physician: a dream not deferred. In: White EC, ed. *The Black Women's Health Book: Speaking for Ourselves.* Seattle, Wash: Seal Press; 1990:52-64.
  - Prescribing information:
    - Januvia [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; February 2013.
  - Scientific presentation:
    - Davis TM, Yeap B, Bruce DG, Davis WA. Lipid-lowering therapy protects against peripheral sensory neuropathy in type 2 diabetes. Presented at: 67th Scientific Sessions. American Diabetes Association Annual Meeting, Chicago, IL, June 22, 2007.



## The New Jersey Journal of Pharmacy Article Cover Sheet

\*The information requested below is requested for all contributing authors

Names of authors in order of which they should appear [corresponding author marked with asterisk]:

Phone:

Email:

Affiliations [if applicable]:

Highest academic degree, position title, and/or academic appointment:

Article Title:

Abstract (300 word maximum):

New Jersey Journal of Pharmacy Disclosure Statement:



To ensure independence in journal article submissions, authors must disclose any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the article. Disclosures pertain to relationships with any drug products, pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the specific presentation topic. In the event there is a conflict, a suitable acknowledgment or disclaimer must be provided to the readers of the journal. The intent of this policy is not to prevent an author with potential conflict of interest from submitting an article, but rather, it is intended that any potential conflict should be identified openly so readers may form their own judgments about the presentation with full disclosure of the facts. It is up to the reader to determine whether the speaker's outside interests may reflect a possible bias in either the discussion or conclusions presented.

I have no actual or potential conflict of interest in relation to this activity.

---

Signature \_\_\_\_\_ Date \_\_\_\_\_

I have or have had a financial interest/arrangement or affiliation with one or more commercial interests that could be perceived as a real or apparent conflict of interest in the context of the subject of this article, including but not limited to: consulting; a family member employed by the organization; a fiduciary responsibility; membership on a governing board; recipient of a grant or research support; a major stockholder; salary, royalty, other financial or material support; and/or membership on a speaker's bureau.

Name of Commercial Interest	Nature of Relationship
_____	_____
_____	_____

---

Signature \_\_\_\_\_ Date \_\_\_\_\_